Oral anthelmintics
The treatment of choice is a single dose of oral ivermectin, which is usually curative.[22]Blackwell V, Vega-Lopez F. Cutaneous larva migrans: clinical features and management of 44 cases presenting in the returning traveller. Br J Dermatol. 2001 Sep;145(3):434-7.
http://www.ncbi.nlm.nih.gov/pubmed/11531833?tool=bestpractice.com
[30]Bouchaud O, Houzé S, Schiemann R, et al. Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin. Clin Infect Dis. 2000 Aug;31(2):493-8. [Erratum in: Clin Infect Dis. 2001 Feb 1;32(3):523.]
https://academic.oup.com/cid/article/31/2/493/296786
http://www.ncbi.nlm.nih.gov/pubmed/10987711?tool=bestpractice.com
Response rates are poorer in cases of CLM-associated folliculitis and repeated courses may be required.[46]Vanhaecke C, Perignon A, Monsel G, et al. The efficacy of single dose ivermectin in the treatment of hookworm related cutaneous larva migrans varies depending on the clinical presentation. J Eur Acad Dermatol Venereol. 2014 May;28(5):655-7.
http://www.ncbi.nlm.nih.gov/pubmed/23368818?tool=bestpractice.com
Adverse effects are rare, although local bullous reactions have been reported. Ivermectin is not approved by the US Food and Drug Administration for the treatment of CLM so patients should be counselled about off-label use.[2]Centers for Disease Control and Prevention. CDC Yellow Book 2024: health Information for international travel. Section 5: travel-associated infections & diseases - cutaneous larva migrans. May 2023 [internet publication].
https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/cutaneous-larva-migrans
It should be avoided in children weighing <15 kg, due to limited clinical experience.
Oral albendazole is an acceptable alternative to ivermectin, although single-dose treatment results in lower cure rates.[30]Bouchaud O, Houzé S, Schiemann R, et al. Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin. Clin Infect Dis. 2000 Aug;31(2):493-8. [Erratum in: Clin Infect Dis. 2001 Feb 1;32(3):523.]
https://academic.oup.com/cid/article/31/2/493/296786
http://www.ncbi.nlm.nih.gov/pubmed/10987711?tool=bestpractice.com
[47]Caumes E, Carrière J, Guermonprez G, et al. Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Infect Dis. 1995 Mar;20(3):542-8.
http://www.ncbi.nlm.nih.gov/pubmed/7756473?tool=bestpractice.com
[48]Van den Enden E, Stevens A, Van Gompel A. Treatment of cutaneous larva migrans. N Engl J Med. 1998 Oct 22;339(17):1246-7.
http://www.ncbi.nlm.nih.gov/pubmed/9786758?tool=bestpractice.com
[49]Caumes E, Carrière J, Datry A, et al. A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop Med Hyg. 1993 Nov;49(5):641-4.
http://www.ncbi.nlm.nih.gov/pubmed/8250105?tool=bestpractice.com
Cure rates for 3 to 5 days of treatment match those of ivermectin, ranging from 77% to 100%.[4]Davies HD, Sakuls P, Keystone JS. Creeping eruption. A review of clinical presentation and management of 60 cases presenting to a tropical disease unit. Arch Dermatol. 1993 May;129(5):588-91.
http://www.ncbi.nlm.nih.gov/pubmed/8481019?tool=bestpractice.com
[22]Blackwell V, Vega-Lopez F. Cutaneous larva migrans: clinical features and management of 44 cases presenting in the returning traveller. Br J Dermatol. 2001 Sep;145(3):434-7.
http://www.ncbi.nlm.nih.gov/pubmed/11531833?tool=bestpractice.com
[50]Jones SK, Reynolds NJ, Oliwiecki S, et al. Oral albendazole for the treatment of cutaneous larva migrans. Br J Dermatol. 1990 Jan;122(1):99-101.
http://www.ncbi.nlm.nih.gov/pubmed/2297509?tool=bestpractice.com
Adverse effects are minimal and mostly consist of mild nausea, vomiting, and headache. Albendazole should be avoided in children <1 year of age, owing to limited clinical experience.
Oral tiabendazole was available in the past for treating CLM but has now been discontinued in some countries.[3]Tremblay A, MacLean JD, Gyorkos T, et al. Outbreak of cutaneous larva migrans in a group of travellers. Trop Med Int Health. 2000 May;5(5):330-34.
http://onlinelibrary.wiley.com/doi/10.1046/j.1365-3156.2000.00557.x/full
http://www.ncbi.nlm.nih.gov/pubmed/10886795?tool=bestpractice.com
[4]Davies HD, Sakuls P, Keystone JS. Creeping eruption. A review of clinical presentation and management of 60 cases presenting to a tropical disease unit. Arch Dermatol. 1993 May;129(5):588-91.
http://www.ncbi.nlm.nih.gov/pubmed/8481019?tool=bestpractice.com
While tiabendazole was effective in treating CLM, the much higher incidence of adverse effects (mostly gastrointestinal) associated with its use resulted in ivermectin and albendazole being the preferred treatment choices.[51]Stone OJ, Mullins JF. Thiabendazole effectiveness in creeping eruption. Arch Dermatol. 1965 May;91:427-9.
http://www.ncbi.nlm.nih.gov/pubmed/14275878?tool=bestpractice.com
Data on the use of ivermectin and albendazole in pregnancy are lacking, although for both drugs, animal studies have shown evidence of teratogenicity. Therefore, treatment should either be delayed until after pregnancy (if symptoms have not yet resolved spontaneously) or supervised by a tropical medicine specialist.
If there is no response to initial treatment after 1 to 2 weeks (no reduction in pruritus or the creeping eruption), treatment can be repeated using the same drug and dose.[30]Bouchaud O, Houzé S, Schiemann R, et al. Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin. Clin Infect Dis. 2000 Aug;31(2):493-8. [Erratum in: Clin Infect Dis. 2001 Feb 1;32(3):523.]
https://academic.oup.com/cid/article/31/2/493/296786
http://www.ncbi.nlm.nih.gov/pubmed/10987711?tool=bestpractice.com
In a small minority of cases, a third course of treatment may be required (e.g., if folliculitis present).[5]Caumes E, Ly F, Bricaire F. Cutaneous larva migrans with folliculitis: report of seven cases and review of the literature. Br J Dermatol. 2002 Feb;146(2):314-6.
http://www.ncbi.nlm.nih.gov/pubmed/11903247?tool=bestpractice.com
However, if symptoms and signs have not resolved after 2 courses of treatment, referral to a tropical-medicine specialist and/or investigation of alternative diagnoses should be considered.
Symptoms and skin findings may recur after an initial positive response to treatment, probably because the hookworm larvae were damaged but not completely killed. Relapse usually occurs within weeks of the initial presentation and responds in most cases to a repeated course of treatment.[3]Tremblay A, MacLean JD, Gyorkos T, et al. Outbreak of cutaneous larva migrans in a group of travellers. Trop Med Int Health. 2000 May;5(5):330-34.
http://onlinelibrary.wiley.com/doi/10.1046/j.1365-3156.2000.00557.x/full
http://www.ncbi.nlm.nih.gov/pubmed/10886795?tool=bestpractice.com
[22]Blackwell V, Vega-Lopez F. Cutaneous larva migrans: clinical features and management of 44 cases presenting in the returning traveller. Br J Dermatol. 2001 Sep;145(3):434-7.
http://www.ncbi.nlm.nih.gov/pubmed/11531833?tool=bestpractice.com
[30]Bouchaud O, Houzé S, Schiemann R, et al. Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin. Clin Infect Dis. 2000 Aug;31(2):493-8. [Erratum in: Clin Infect Dis. 2001 Feb 1;32(3):523.]
https://academic.oup.com/cid/article/31/2/493/296786
http://www.ncbi.nlm.nih.gov/pubmed/10987711?tool=bestpractice.com